Humphries, MP orcid.org/0000-0003-1306-7012, Rajan, SS, Droop, A orcid.org/0000-0001-7695-7480 et al. (29 more authors) (2017) A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer. Clinical Cancer Research, 23 (10). pp. 2575-2583. ISSN 1078-0432
Abstract
Purpose: Breast cancer (BC) affects both genders, but is understudied in men. Although still rare, male BC is being diagnosed more frequently. Treatments are wholly informed by clinical studies conducted in women, based on assumptions that underlying biology is similar. Experimental design: A transcriptomic investigation of male and female BC was performed, confirming transcriptomic data in silico. Biomarkers were immunohistochemically assessed in 697 MBCs (n=477, training; n=220, validation set) and quantified in pre- and post-treatment samples from a male BC patient receiving Everolimus and PI3K/mTOR inhibitor. Results: Gender-specific gene expression patterns were identified. eIF transcripts were up-regulated in MBC. eIF4E and eIF5 were negatively prognostic for overall survival alone (Log rank; p=0.013; HR=1.77, 1.12-2.8 and p=0.035; HR=1.68, 1.03-2.74, respectively), or when co-expressed (p=0.01; HR=2.66, 1.26-5.63), confirmed in the validation set. This remained upon multivariate Cox regression analysis (eIF4E p=0.016; HR 2.38 (1.18-4.8), eIF5 p=0.022; HR 2.55 (1.14-5.7); co-expression p=0.001; HR=7.04 (2.22-22.26)). Marked reduction in eIF4E and eIF5 expression was seen post BEZ235/Everolimus, with extended survival. Conclusions: Translational initiation pathway inhibition could be of clinical utility in male BC patients overexpressing eIF4E and eIF5. With mTOR inhibitors which target this pathway now in the clinic, these biomarkers may represent new targets for therapeutic intervention, although further independent validation is required.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016, American Association for Cancer Research. This is an author produced version of a paper published in Clinical Cancer Research. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | breast cancer; genomics; eIF; survival; mTOR inhibitor |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds) |
Funding Information: | Funder Grant number Yorkshire Cancer Research L378 Expired: Use BreastCancerNow 605321 NOT GIVEN Yorkshire Cancer Research LPP030 Breast Cancer Cure NZ NONE GIVEN |
Depositing User: | Symplectic Publications |
Date Deposited: | 16 Dec 2016 12:55 |
Last Modified: | 16 Dec 2017 01:38 |
Published Version: | https://doi.org/10.1158/1078-0432.CCR-16-1952 |
Status: | Published |
Publisher: | American Association for Cancer Research |
Identification Number: | 10.1158/1078-0432.CCR-16-1952 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:109588 |